Although we verified that BCL2L1 does play a role in driving MCL1 inhibitor response in gliomas, our approach of integration of multiomics molecular and functional analyses identified an unprecedented ability of BCL2L1 methylation at an exonic-intronic region (N-shore of CpG island) to predict MCL1 inhibitor response in pHGGs compared with aHGGs. The gene discussed is MCL1; the disease is central nervous system cancer.